Citius Oncology Deploys AI Platform to Amplify Commercial Team Ahead of LYMPHIR Launch

Citius Oncology has deployed an AI platform to support its commercial team ahead of the launch of LYMPHIR, a novel therapy for cutaneous T-cell lymphoma. The platform uses machine learning to identify patterns in treatment and diagnosis, enabling the commercial team to target prescribers whose patients may benefit from LYMPHIR. The AI platform adapts over time through ongoing integration of real-world data and marketing performance analytics. This enhances the precision and impact of targeting and engagement, allowing the commercial team to support more informed patient care.